Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Stanford Health Care

The safety and efficacy of dexamethasone in the perioperative management of glioma patients.

The safety and efficacy of dexamethasone in the perioperative management of glioma patients. Journal of neurosurgery Medikonda, R., Patel, K., Jackson, C., Saleh, L., Srivastava, S., Feghali, J., Mohan, A., Pant, A., Jackson, C. M., Weingart, J., Mukherjee, D., Bettegowda, C., Gallia, G. L., Brem, H., Lim, M. 2021: 1-8

Abstract

In this single-institution retrospective cohort study, the authors evaluated the effect of dexamethasone on postoperative complications and overall survival in patients with glioma undergoing resection.A total of 435 patients who underwent resection of a primary glioma were included in this retrospective cohort study. The inclusion criterion was all patients who underwent resection of a primary glioma at a tertiary medical center between 2014 and 2019.The use of both pre- and postoperative dexamethasone demonstrated a trend toward the development of postoperative wound infections (3% vs 0% in single use or no use, p = 0.082). No association was detected between dexamethasone use and the development of new-onset hyperglycemia (p = 0.149). On multivariable Cox proportional hazards analysis, dexamethasone use was associated with a greater hazard of death (overall p = 0.017); this effect was most pronounced for preoperative (only) dexamethasone use (hazard ratio 3.0, p = 0.062).Combined pre- and postoperative dexamethasone use may increase the risk of postoperative wound infection, and dexamethasone use, specifically preoperative use, may negatively impact survival. These findings highlight the potential for serious negative consequences with dexamethasone use.

View details for DOI 10.3171/2021.4.JNS204127

View details for PubMedID 34560653